GPR119 Agonist Compounds for Glycemic Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly type 2 diabetes, offer limited improvement in glycaemic control and are associated with deterioration in beta cell function, leading to complications such as cardiovascular disease, nephropathy, and neuropathy, with a need for medications that effectively manage metabolic disorders without causing hypoglycemia.
Innovation Solution
Development of new 2,3-dihydro-furo[2,3-c]pyridine derivatives that act as GPR119 agonists, activating the G-protein-coupled receptor GPR119 to stimulate insulin secretion and improve beta cell function, thereby facilitating glycemic control and weight loss without the risk of hypoglycemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If intensive treatment with common therapeutic agents (metformin, sulphonylureas, or insulin) is used, then glycaemic control is improved, but beta cell function deteriorates over time
Solution Approach 1:
The patent employs parameter changes by developing novel chemical compounds with modified molecular structures (formula I with specific R1, A, and T groups) that interact differently with the GPR119 receptor compared to existing therapies. This structural parameter change enables selective activation of GPR119, triggering a unique signaling cascade that improves glycaemic control while preserving beta cell function through enhanced insulin secretion and beta cell protection mechanisms.
Solution Approach 2:
The invention introduces GPR119 as an intermediary target in the therapeutic pathway. Rather than directly affecting beta cells or insulin action, the compounds act through GPR119 activation, which serves as a mediator to indirectly improve glycaemic control. This intermediary mechanism allows for improved glucose management while avoiding the direct beta cell stress associated with conventional treatments.
2Measurement precision
If conventional diabetes treatments are used, then glycaemic control is improved, but risk of cardiovascular disease increases
Solution Approach 1:
The patent applies the blessing in disguise principle by converting the potential harm of intensive glycaemic control (which can lead to cardiovascular complications) into a benefit. The GPR119 agonist compounds achieve glycaemic control through a mechanism that simultaneously provides cardiovascular protection by improving lipid profiles, reducing inflammation, and enhancing insulin sensitivity, thereby transforming a potentially harmful treatment approach into a beneficial one.
Solution Approach 2:
The invention embodies universality by designing compounds that perform multiple therapeutic functions simultaneously. The GPR119 agonists not only improve glycaemic control but also provide cardiovascular protection, anti-inflammatory effects, and metabolic improvement. This multi-functional approach allows a single compound to address multiple aspects of metabolic syndrome and diabetes complications, reducing the need for combination therapies that increase cardiovascular risk.
3Measurement precision
If existing diabetes medications are used, then glycaemic control is improved, but safety profile deteriorates due to hypoglycemia risk
Solution Approach 1:
The patent implements feedback control through the glucose-dependent mechanism of GPR119 activation. The compounds enhance insulin secretion in a glucose-dependent manner, meaning that insulin release is stimulated only when blood glucose levels are elevated. This built-in feedback mechanism prevents hypoglycemia by automatically reducing insulin secretion when glucose levels return to normal, thereby maintaining safe glycaemic control without the hypoglycemia risk associated with conventional insulin secretagogues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively lower blood glucose levels, improve insulin secretion, and promote weight loss, making them suitable for treating diabetes, dyslipidemia, and obesity while maintaining a better safety profile compared to existing treatments.
Implementation Method 1
GPR119 is a G-protein coupled receptor (also known as GPCR2, RUP3, SNORF25 or GDIR) which is expressed predominantly in the beta cells of the pancreas and in the K- and L-cells of the intestine. Activation of the receptor stimulates the cAMP signal pathway, increasing the intracellular levels of cAMP in these cells.
Implementation Method 2
Activation of the receptor stimulates the cAMP signal pathway, increasing the intracellular levels of cAMP in these cells. This will lead to an improved diabetic situation by a dual action of such a compound: stimulation of cAMP in the beta cell occurs directly via activation of GPR119 in these cells and furthermore indirectly via stimulation of the release of neuroendocrine peptides like GIP and GLP-1 and PYY from the gut.
Data Source
AI summary
The present invention relates to compounds of general formula I, wherein the groups R1 and A are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.